Progressive supranuclear palsy: Clinical features and response to treatment in 16 patients

Jeffrey J. Jackson, Joseph Jankovic, Janet Ford

Research output: Contribution to journalArticlepeer-review

126 Scopus citations

Abstract

Among 415 patients with parkinsonism, 16 (3.9%) had findings of progressive supranuclear palsy (PSP). This report reviews the clinical features and response to drug therapy in those 16 patients. Anticholinergic drugs failed to benefit any of the 5 patients treated, while presynaptic dopaminergic drugs (Sinemet or amantadine) were beneficial in only 5 of 22 patient trials. Alternatively, dopamine agonists (bromocriptine and pergolide) caused improvement in 9 of 14 patient trials despite the fact that all but 1 of these patients had previously failed to respond to presynaptic dopaminergic drugs. Dopamine agonists such as bromocriptine and pergolide may be useful in some patients with PSP.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalAnnals of Neurology
Volume13
Issue number3
DOIs
StatePublished - Jan 1 1983

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Progressive supranuclear palsy: Clinical features and response to treatment in 16 patients'. Together they form a unique fingerprint.

Cite this